Antibody-dependent cellular cytotoxicity of the optimized anti-CD20 monoclonal antibody ublituximab on chronic lymphocytic leukemia cells with the 17p deletion von Le Garff-Tavernier, M, Herbi, L, de Romeuf, C, Nguyen-Khac, F, Davi, F, Grelier, A, Boudjoghra, M, Maloum, K, Choquet, S, Urbain, R, Vieillard, V, Merle-Béral, H

Volltext

Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies von Le Garff-Tavernier, M, Decocq, J, de Romeuf, C, Parizot, C, Dutertre, C A, Chapiro, E, Davi, F, Debré, P, Prost, J F, Teillaud, J L, Merle-Beral, H, Vieillard, V

Volltext

The optimized anti-CD20 monoclonal antibody ublituximab bypasses natural killer phenotypic features in Waldenström macroglobulinemia von Le Garff-Tavernier, Magali, Herbi, Linda, de Romeuf, Christophe, Azar, Nabih, Roos-Weil, Damien, Bonnemye, Patrick, Urbain, Rémi, Leblond, Véronique, Merle-Beral, Hélène, Vieillard, Vincent

Volltext

Selection of a human anti-RhD monoclonal antibody for therapeutic use: Impact of IgG glycosylation on activating and inhibitory FcγR functions von Sibéril, Sophie, de Romeuf, Christophe, Bihoreau, Nicolas, Fernandez, Nadine, Meterreau, Jean-Luc, Regenman, Annie, Nony, Emmanuel, Gaucher, Christine, Glacet, Arnaud, Jorieux, Sylvie, Klein, Philippe, Hogarth, Mark P., Fridman, Wolf-Herman, Bourel, Dominique, Béliard, Roland, Teillaud, Jean-Luc

Volltext

R108: Ingénierie génétique de la région Fc des anticorps humains en vue d’améliorer leur demi-vie plasmatique von Monnet, C., Jorieux, S., Souyris, N., Zaki, O., Morlec, R., Crozet, F., Fontayne, A., De Romeuf, C., Kharrat, H., Urbain, R., Bouayadi, K., Behrens, C., Mondon, P.

Volltext

Analysis of [CD16.sup.+] [CD56.sup.dim] NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies von de Romeuf, C, Chapiro, E, Davi, F, Teillaud, J.L, Merle-Beral, H, Vieillard, V, Dutertre, C.A, Prost, J.F, Le Garff-Tavernier, M, Decocq, J, Parizot, C, Debre, P

Volltext

Circulating von Willebrand factor antigen II in atherosclerosis: a comparison with von Willebrand factor and soluble thrombomodulin von Blann, A D, de Romeuf, C, Mazurier, C, McCollum, C N

Volltext

Analysis of CD16 super(+)CD56 super(dim) NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies von Le Garff-Tavernier, M, Decocq, J, de Romeuf, C, Parizot, C, Dutertre, C A, Chapiro, E, Davi, F, Debre, P, Prost, J F, Teillaud, J L, Merle-Beral, H, Vieillard, V

Volltext

Adhesive properties of the carbohydrate-modified von Willebrand factor (CHO-vWF) von Federici, AB, De Romeuf, C, De Groot, PG, Samor, B, Lombardi, R, D'Alessio, P, Mazurier, C, Mannucci, PM, Sixma, JJ

Volltext

Leu 697-->Val mutation in mature von Willebrand factor is responsible for type IIB von Willebrand disease von Hilbert, L, Gaucher, C, de Romeuf, C, Horellou, MH, Vink, T, Mazurier, C

Volltext

INTEREST OF A SIMPLE AND FAST METHOD FOR PLATELET VON WILLEBRAND FACTOR CHARACTERIZATION von de Romeuf, Christophe, Mazurier, Claudine

Volltext

Section 1C: Assessment of the functional activity and IgG Fc receptor utilisation of 64 IgG Rh monoclonal antibodies. Coordinator’s report von Kumpel, B.M, Beliard, R, Brossard, Y, Edelman, L, de Haas, M, Jackson, D.J, Kooyman, P, Ligthart, P.C, Monchâtre, E, Overbeeke, M.A.M, Puillandre, P, de Romeuf, C, Wilkes, A.M

Volltext

Leu 697 → Val mutation in mature von Willebrand factor is responsible for type IIB von Willebrand disease von HILBERT, L, GAUCHER, C, DE ROMEUF, C, HORELLOU, M.-H, VINK, T, MAZURIER, C

Volltext

Antibody-dependent cellular cytotoxicity of the optimized anti-CD20 monoclonal antibody ublituximab on chronic lymphocytic leukemia cells with the 17p deletion von Garff-Tavernier, M.Le, Herbi, L, de Romeuf, C, Nguyen-Khac, F, Davi, F, Grelier, A, Boudjoghra, M, Maloum, K, Choquet, S, Urbain, R, Vieillard, V, Merle-Beral, H

Volltext

Heterogeneity of microfibrils : role of thrombospondin-microfibrils in the thrombogenicity of the subendothelium von FAUVEL-LAFEVE, F, ARBEILLE, B, DE ROMEUF, C, LEMESLE, M, LEGRAND, Y. J

Volltext

Analysis of [CD16.sup.+] [CD56.sup.dim] NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies von Le Garff-Tavernier, M, Decocq, J, de Romeuf, C, Parizot, C, Dutertre, C.A, Chapiro, E, Davi, F, Debre, P, Prost, J.F, Teillaud, J.L, Merle-Beral, H, Vieillard, V

Volltext

Adhesive Properties of the Carbohydrate-Modified von Willebrand Factor (CHO-vWF) von Federici, Augusto B., Romeuf, Christophe De, De Groot, Phlip G., Samor, Bruno, Lombardi, Rossana, D’Alessio, Patrizia, Mazurier, Claudine, Mannucci, Pier Mannuccio, Sixma, Jan J.

Volltext

Selection of IgG Variants with Increased FcRn Binding Using Random and Directed Mutagenesis: Impact on Effector Functions von Monnet, Céline, Jorieux, Sylvie, Urbain, Rémi, Fournier, Nathalie, Bouayadi, Khalil, De Romeuf, Christophe, Behrens, Christian K, Fontayne, Alexandre, Mondon, Philippe

Volltext

Transgenic goats producing an improved version of cetuximab in milk von Laible, Götz, Cole, Sally, Brophy, Brigid, Maclean, Paul, How Chen, Li, Pollock, Dan P., Cavacini, Lisa, Fournier, Nathalie, De Romeuf, Christophe, Masiello, Nicholas C., Gavin, William G., Wells, David N., Meade, Harry M.

Volltext

EMABling®, une technologie stimulant l’activité effectrice des anticorps monoclonaux von de Romeuf, Christophe

Volltext